Clinical trial
Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside…
NCT00004985 · Agouron Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00004985 |
|---|---|
| Title | Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy |
| Official title | A Phase II, Single-Blind, Randomized, Placebo-Controlled Study of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Subjects Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen |
| Lead sponsor | Agouron Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Capravirine, Nelfinavir mesylate |
| Enrollment | 75 |
| Start date | Jan 1, 2000 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: